First Survival Drug for Niemann-Pick Disease; mRNA Melanoma Vaccine Shows Durable Benefit
FDA clears first survival drug for Niemann-Pick disease type C, mRNA melanoma vaccine proves durable in phase 3, and Ebola holds at 11,463.
By Dr. Asher Knippel
The week of 17 November brought a rare-disease landmark, two targeted oncology milestones, compelling mRNA cancer-vaccine data from a major phase 3 trial, a pediatric obesity readout, and ongoing surveillance of two active public-health emergencies.
Monday, 17 November: FDA Approves First Drug to Extend Survival in Niemann-Pick Disease Type C
The U.S. Food and Drug Administration approved Lembaz (adrabetadex) on 17 November for infantile-onset Niemann-Pick disease type C (NPC), marking the first treatment shown to extend the survival of patients with this rare, devastating lysosomal storage disorder. NPC arises from a genetic defect that traps cholesterol within lysosomes, gradually destroying the nervous system; children with the infantile-onset form typically decline rapidly and die before adulthood. Adrabetadex works as a cyclodextrin — a ring-shaped sugar molecule — that acts as a shuttle, helping cells extract and export the trapped cholesterol. The approval rested on a clinical trial demonstrating prolonged survival in treated patients compared with standard care, an endpoint no previous drug had achieved for this indication. The FDA's decision gives families facing this diagnosis, for the first time, a medicine backed by survival data.
Sunday, 16 November: Giredestrant Approved for ESR1-Mutated Breast Cancer
The FDA approved Wilserdly (giredestrant) on 16 November for adults with locally advanced or metastatic oestrogen-receptor–positive, HER2-negative breast cancer carrying an ESR1 mutation, whose disease had progressed on a prior hormone therapy. ESR1 mutations are the most common resistance mechanism to aromatase inhibitors — the standard backbone of endocrine therapy — and they emerge in roughly 20–40% of patients after first-line treatment. Giredestrant is an oral selective oestrogen-receptor degrader (SERD) that retains activity against a broad range of ESR1 mutation variants, including the rarer D538G and L536R substitutions. Having an additional oral option in this space is clinically meaningful: patients who develop resistance to or cannot tolerate existing SERDs now have an agent from a distinct chemical scaffold. The FDA's approval was supported by a randomised clinical trial showing improved progression-free survival in this molecularly defined population.
Tuesday, 11 November: mRNA Melanoma Vaccine plus Pembrolizumab Prolongs Recurrence-Free Survival
A personalised mRNA cancer vaccine, intismeran autogene (also known as V940), significantly prolonged recurrence-free survival when added to pembrolizumab in patients who had undergone surgery for stage IIB–IV melanoma, according to a Phase 3 trial published 11 November in the New England Journal of Medicine. The vaccine is manufactured individually for each patient: tumour biopsy DNA is sequenced, up to 34 neoantigens unique to that person's cancer are encoded into an mRNA construct, and the resulting vaccine is infused over several sessions to train the immune system to recognise those cancer-specific targets. In the trial, patients who received the combination showed significantly better recurrence-free survival than those who received pembrolizumab alone, extending a signal first seen in a Phase 2 readout in 2023. The result represents a meaningful step toward personalised cancer immunotherapy — though intismeran has not yet received regulatory approval, and confirmatory data from larger populations will be needed before it enters standard practice.
Sunday, 16 November: Semaglutide Reduces BMI by 13% in Children as Young as Six
A Phase 3 randomised controlled trial published in the New England Journal of Medicine on 16 November found that weekly semaglutide injections reduced body-mass index by 13.5% at week 68 in children aged 6 to under 12 with obesity, compared with a 2.7% increase in the placebo group — a difference of roughly 16 percentage points. At two years (week 104), the treated group showed a 9.4% BMI reduction versus an 8.4% rise in the placebo group, suggesting durable benefit. Semaglutide, a GLP-1 receptor agonist, was already approved for obesity in adolescents and adults; this trial, funded by Novo Nordisk, extends the evidence base into primary-school-age children. Investigators reported improvements in cardiometabolic markers alongside weight reduction. Childhood obesity substantially raises lifetime risk of type 2 diabetes, cardiovascular disease, and musculoskeletal complications, making earlier intervention a public-health priority — though long-term safety data for GLP-1 use in this younger age group are still accumulating, and clinical judgement about individual circumstances remains essential.
Ongoing — DRC Ebola Bundibugyo Outbreak Holds above 11,000; Travel Protocols in Force
The Democratic Republic of the Congo Ebola outbreak caused by the Bundibugyo virus strain continues to be tracked closely by international public-health bodies. As of 15 November 2026, the European Centre for Disease Prevention and Control recorded 11,463 total confirmed cases and 5,597 confirmed deaths, almost entirely within the DRC. The World Health Organization declared a Public Health Emergency of International Concern on 17 May 2026; Africa CDC declared a continental public-health emergency the following day. The U.S. Centers for Disease Control and Prevention confirmed as of 17 November that no cases have been identified in the United States, and the overall risk to international travellers remains classified as low. Since 3 November, passengers arriving in the United States from the DRC have been required to attest they were not in the country during the prior 21 days. ECDC cautions that actual case counts may exceed current figures owing to surveillance capacity limitations in affected areas — a pattern common in complex humanitarian emergencies.
Monday, 17 November: FDA Launches Global Reliance Disclosure Programme
The FDA introduced a Global Reliance Disclosure Programme on 17 November, a new mechanism designed to expand patient access to medicines already approved by trusted foreign regulatory authorities. Under the programme, sponsors holding approval from a designated partner — including the European Medicines Agency, Australia's Therapeutic Goods Administration, or Health Canada — may disclose that approval to the FDA, allowing the agency to incorporate that overseas decision into its own review. The goal is to reduce regulatory duplication and accelerate the U.S. timeline for drugs that have already cleared rigorous overseas scrutiny. For patients in countries where the inverse relationship applies — such as EU member states seeking access to FDA-approved medicines — such mutual-recognition frameworks have historically eased access as well, though the practical effects of this programme will depend on implementation guidance still to be published.
The content in this roundup is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management.